Recent Company News

• 03:15 PM ET Oct 01, 2026
  

  Weekly Losses Deepen As Small Caps Lag And Yields Edge Higher Into Earnings Gauntlet

• 04:10 PM ET Sep 30, 2026
  

  RedHill Biopharma reports H1 net income ($6.1M) vs year-ago ($4.1M) ($0.48, 0.00)

• 04:05 PM ET Sep 30, 2026
  

  RedHill Biopharma Announces Operational Highlights and First Half 2026 Financial Results

• 09:03 AM ET Sep 10, 2026
  

  Jaguar Health announces all randomized pediatric patients to continue in the single-blind extension phase of clinical trial of crofelemer for microvillus inclusion disease (MVID) with intestinal failure (if) ($0.37, 0.00)

• 07:04 AM ET Sep 01, 2026
  

  RedHill Biopharma announces acquisition of exclusive global and U.S. commercialization rights to Rebyota and Clenpiq, from Ferring Pharmaceuticals ($0.90, 0.00)

• 07:00 AM ET Sep 01, 2026
  

  RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®

• 07:05 AM ET Aug 31, 2026
  

  RedHill Biopharma divests Talicia to Apotex for $18M cash upfront plus milestones ($0.66, 0.00)

• 07:01 AM ET Aug 31, 2026
  

  RedHill Divests Talicia(EQNX::registered) to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities